AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8928758 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I (80 micrograms.kg‐1.day‐1 sc)
Number of subjects: 26
Study 8928758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline sc)
Number of subjects: 26
Study 1336292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 37
Study 1336292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3882269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (1 mg/kg followed by 25 micrograms/kg/min over 36 hr)
Number of subjects: 30
Study 3882269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29020467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1,064 nm laser plus 4% hydroquinone cream
Number of subjects: 30
Study 29020467 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream only
Number of subjects: 30
Study 25900347 — intervention group
Group type: COMPARATOR
Intervention: 3 g daily of placebo gel applied topically + periodontal debridement
Number of subjects: 30
Study 25900347 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g daily of a 15% Mtz benzoate gel applied topically + periodontal debridement
Number of subjects: 30
Study 25900347 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg Mtz (Flagyl(®)) daily single dose + periodontal debridement
Number of subjects: 30
Study 24793627 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary axillary lymph node dissection (ALND) with positive sentinel node
Number of subjects: 0
Study 24793627 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study 22594373 — intervention group
Group type: EXPERIMENTAL
Intervention: The Practical Guide of PE (bibliotherapy)
Number of subjects: 421
Study 22594373 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 421
Study 20127212 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous indwelling vacuum drainage
Number of subjects: 111
Study 20127212 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular indwelling vacuum drainage
Number of subjects: 111
Study 18540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 0
Study 18540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 18540740 — intervention group
Group type: COMPARATOR
Intervention: Medication (withdrawn onto pill-placebo)
Number of subjects: 0
Study 18540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication continuation
Number of subjects: 0
Study 16287349 — intervention group
Group type: EXPERIMENTAL
Intervention: CE (Concentric and Eccentric phases)
Number of subjects: 47
Study 16287349 — intervention group
Group type: COMPARATOR
Intervention: CT (Control group)
Number of subjects: 47
Study 12351550 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted ICSI (LA-ICSI)
Number of subjects: 32
Study 12351550 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICSI (C-ICSI)
Number of subjects: 32
Study 10202604 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E2)
Number of subjects: 12
Study 10202604 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 12
Study 7594103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sematilide (0.75 then 0.3 mg/min)
Number of subjects: 39
Study 7594103 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose sematilide (1.5 then 0.6 mg/min)
Number of subjects: 39
Study 7594103 — intervention group
Group type: COMPARATOR
Intervention: Neither low nor high dose sematilide
Number of subjects: 39
Study 7594103 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose sematilide
Number of subjects: 39
Study 2316419 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 9
Study 2316419 — intervention group
Group type: COMPARATOR
Intervention: Hospital wards
Number of subjects: 9
Study 7367152 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program designed to promote self‐generation of strategies using self‐verbalization
Number of subjects: 41
Study 7367152 — intervention group
Group type: COMPARATOR
Intervention: Normal training program of the centre
Number of subjects: 41
Study 30741884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predicting risk of interventions for bleeding after high-grade renal trauma
Number of subjects: 326
Study 27841822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.01 to 0.06 U/min)
Number of subjects: 300
Study 27841822 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (10 to 60 μg/min)
Number of subjects: 300
Study 27841822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 300
Study 27841822 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 300
Study 26231757 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT intervention delivered by dietitians during usual consultations, based on behaviour change counselling methods including motivational interviewing and cognitive-behavioural therapy.
Number of subjects: 400
Study 26231757 — intervention group
Group type: COMPARATOR
Intervention: Control condition providing treatment as usual before switching to EAT intervention.
Number of subjects: 400
Study 24169061 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms/day
Number of subjects: 0
Study 24169061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21507143 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance for antibiotic treatment
Number of subjects: 172
Study 21507143 — intervention group
Group type: COMPARATOR
Intervention: Control group (current guidelines for antibiotic treatment)
Number of subjects: 172
Study 19476770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral discussion and written pamphlet outlining the risks of the procedure
Number of subjects: 100
Study 19476770 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral dialogue of the surgical risks
Number of subjects: 100
Study 17297625 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Intermittent Hypoxia (SIH) - 12% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30
Study 17297625 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intermittent Hypoxia (MIH) - 15% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30
Study 17297625 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - 21% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30
Study 15848979 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization appliance (group T)
Number of subjects: 60
Study 15848979 — intervention group
Group type: COMPARATOR
Intervention: Control appliance (group C)
Number of subjects: 60
Study 15848979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (group M)
Number of subjects: 60
Study 11484097 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year exercise training
Number of subjects: 35
Study 11484097 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year exercise training plus 1-year detraining
Number of subjects: 35
Study 11484097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 9495424 — intervention group
Group type: COMPARATOR
Intervention: Epidural opioids
Number of subjects: 0
Study 9495424 — intervention group
Group type: COMPARATOR
Intervention: Epidural local anesthetics
Number of subjects: 0
Study 9495424 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve blockade
Number of subjects: 0
Study 9495424 — intervention group
Group type: COMPARATOR
Intervention: Surrogate measures of pulmonary function (FEV1, FVC, PEFR)
Number of subjects: 0
Study 8067649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials coupled with a simulated patient instructor office visit
Number of subjects: 757
Study 8067649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials only
Number of subjects: 757
Study 8067649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 757
Study 8067649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group
Number of subjects: 757
Study 8067649 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials only
Number of subjects: 757
Study 8067649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 757
Study 3149771 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg scopolamine
Number of subjects: 0
Study 3149771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30999554 — intervention group
Group type: EXPERIMENTAL
Intervention: AA mixture containing 3600 mg of arginine, 2200 mg of valine, and 200 mg of serine
Number of subjects: 39
Study 30999554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30999554 — intervention group
Group type: EXPERIMENTAL
Intervention: AA mixture
Number of subjects: 39
Study 28678853 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic alendronate (Bonmax®) 70 mg/week
Number of subjects: 140
Study 28678853 — intervention group
Group type: COMPARATOR
Intervention: Brand alendronate (Fosamax®) 70 mg/week
Number of subjects: 140
Study 24699438 — intervention group
Group type: EXPERIMENTAL
Intervention: High background rhythm frequency (BRF)
Number of subjects: 0
Study 24699438 — intervention group
Group type: EXPERIMENTAL
Intervention: More than median theta (θ) band power
Number of subjects: 0
Study 24699438 — intervention group
Group type: COMPARATOR
Intervention: Low background rhythm frequency (BRF)
Number of subjects: 0
Study 24699438 — intervention group
Group type: COMPARATOR
Intervention: Less than median theta (θ) band power
Number of subjects: 0
Study 23535090 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 65
Study 23535090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antihistamines and leukotriene antagonists
Number of subjects: 65
Study 23535090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 65
Study 21638013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz cerebellar repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 20
Study 21638013 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study 19383112 — intervention group
Group type: EXPERIMENTAL
Intervention: 44% oxygen (hyperoxia)
Number of subjects: 51
Study 19383112 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 51
Study 16704575 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 10
Study 16704575 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadspace (DS)
Number of subjects: 10
Study 16704575 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study 15033131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight reduction program
Number of subjects: 31
Study 15033131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight reduction program + CPAP
Number of subjects: 31
Study 11835741 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO), 3 courses of treatment
Number of subjects: 55
Study 11835741 — intervention group
Group type: COMPARATOR
Intervention: Dehydrating, cortical steroid and antibiotic therapy (Control)
Number of subjects: 55
Study 9491904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 10
Study 9491904 — intervention group
Group type: COMPARATOR
Intervention: PMMA membrane
Number of subjects: 10
Study 7818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg
Number of subjects: 12
Study 7818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 12
Study 7818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 8.8 mg
Number of subjects: 12
Study 7818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 17.6 mg
Number of subjects: 12
Study 3061353 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple excision of anal papillae
Number of subjects: 41
Study 3061353 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 41
Study 30110579 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg once daily)
Number of subjects: 431
Study 30110579 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles)
Number of subjects: 431
Study 30110579 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 431
Study 30110579 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 431
Study 26671747 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication (n=19)
Number of subjects: 131
Study 26671747 — intervention group
Group type: COMPARATOR
Intervention: Non-eradicated patients (n=17)
Number of subjects: 131
Study 26671747 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 131
Study 25714598 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab (0.03-20 mg/kg)
Number of subjects: 56
Study 25714598 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab
Number of subjects: 56
Study 25714598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24328444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2584
Study 24328444 — intervention group
Group type: COMPARATOR
Intervention: Control (hepatitis A vaccine)
Number of subjects: 2584
Study 21349483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mEq/L, 0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Number of subjects: 59
Study 21349483 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Number of subjects: 59
Study 18753003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (0.5-4mg/24h)
Number of subjects: 295
Study 12419727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 and 8 microgram*kg(‐1)*min(‐1))
Number of subjects: 14
Study 12419727 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (4 and 8 microgram*kg(‐1)*min(‐1))
Number of subjects: 14
Study 12419727 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dopamine and dobutamine at 8 microgram*kg(‐1)*min(‐1)
Number of subjects: 14
Study 9602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 25 micrograms kg‐1
Number of subjects: 120
Study 9602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg kg‐1
Number of subjects: 120
Study 9602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120
Study 7648115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 168
Study 7648115 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 168
Study 2667745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 100
Study 2667745 — intervention group
Group type: COMPARATOR
Intervention: Control (no tamoxifen therapy)
Number of subjects: 100
Study 318578 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG)
Number of subjects: 2204
Study 318578 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 2204
Study 31074827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk alone (MM)
Number of subjects: 112
Study 31074827 — intervention group
Group type: COMPARATOR
Intervention: Hybrid feed (HF)
Number of subjects: 112
Study 31282592 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg on days 2-7) with Itacitinib (200 mg on days 1 and 6)
Number of subjects: 36
Study 31282592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg on days 2-9) with Itacitinib (200 mg on days 1 and 9)
Number of subjects: 36
Study 27997965 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month reminder plus standard information booklet (TMR-SIB)
Number of subjects: 1383
Study 27997965 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month reminder plus bespoke theory-based leaflet (TMR-TBL)
Number of subjects: 1383
Study 27997965 — intervention group
Group type: COMPARATOR
Intervention: No reminder (control)
Number of subjects: 1383
Study 25915712 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIA psychotherapy sessions up to 3 months postoperatively
Number of subjects: 220
Study 25915712 — intervention group
Group type: COMPARATOR
Intervention: No psychotherapy/computerized brief written advice (BWA)
Number of subjects: 220
Study 23487278 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group intervention at CPAA centers (Group B)
Number of subjects: 188
Study 23487278 — intervention group
Group type: COMPARATOR
Intervention: Standard program for patients and relatives (Group A)
Number of subjects: 188
Study 21831711 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pre-TURBT EMDA mitomycin (40 mg in 100 mL sterile water with 20 mA pulsed electric current for 30 min)
Number of subjects: 374
Study 21831711 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pre-TURBT EMDA mitomycin
Number of subjects: 374
Study 21831711 — intervention group
Group type: COMPARATOR
Intervention: TURBT alone
Number of subjects: 374
Study 21831711 — intervention group
Group type: COMPARATOR
Intervention: Immediate post-TURBT PD mitomycin
Number of subjects: 374
Study 19350369 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized behavioral treatment including motivational interviewing and cognitive therapy
Number of subjects: 14
Study 19350369 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 14
Study 16622140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations for posterior lesions (n = 253)
Number of subjects: 507
Study 16622140 — intervention group
Group type: COMPARATOR
Intervention: Resin composite restorations instead of amalgam (n = 254)
Number of subjects: 507
Study 14977161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler
Number of subjects: 41
Study 14977161 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg gum
Number of subjects: 41
Study 14977161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg gum
Number of subjects: 41
Study 14977161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tablet
Number of subjects: 41
Study 14977161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray
Number of subjects: 41
Study 11430618 — intervention group
Group type: EXPERIMENTAL
Intervention: +/-0.50 D spherical binocular and monocular errors
Number of subjects: 15
Study 11430618 — intervention group
Group type: COMPARATOR
Intervention: Reference pair of spectacles
Number of subjects: 15
Study 9244228 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 to 10 mg)
Number of subjects: 13
Study 9244228 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. saline (1 L)
Number of subjects: 13
Study 9244228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg)
Number of subjects: 13
Study 7957496 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 h of sleeplessness (group A)
Number of subjects: 40
Study 7957496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleep in a seated position for three consecutive nights (group B)
Number of subjects: 40
Study 7957496 — intervention group
Group type: COMPARATOR
Intervention: Controls (group C)
Number of subjects: 40
Study 30056321 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (interactive HIV flipbook and HCV video)
Number of subjects: 25
Study 27165542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylic Salicylic Acid (ASA) 500 mg once daily for 12 weeks
Number of subjects: 40
Study 27165542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24840857 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g day(‐1) for 7 days followed by 5 g day(‐1))
Number of subjects: 32
Study 24840857 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 32
Study 24840857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL-dextrose)
Number of subjects: 32
Study 22342927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 55
Study 22342927 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 55
Study 22342927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 55
Study 19335940 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel cooking pots distributed to households in Nduta camp (intervention)
Number of subjects: 220
Study 19335940 — intervention group
Group type: COMPARATOR
Intervention: Aluminium or clay pots used in households in Mtendeli camp (control)
Number of subjects: 220
Study 18608735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream plus NB-UVB
Number of subjects: 68
Study 18608735 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus NB-UVB
Number of subjects: 68
Study 16797280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Hook F. (T II)
Number of subjects: 223
Study 16797280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T II)
Number of subjects: 223
Study 14572747 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg in addition to standard care
Number of subjects: 0
Study 10701823 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg)
Number of subjects: 154
Study 10701823 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg)
Number of subjects: 154
Study 10701823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9234049 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 6
Study 9234049 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 6